The prognosis of patients with metastatic melanoma remains poor, with a median survival that does not exceed 6 months (Koh, 1991) . Most clinical trials using interleukin 2 in metastatic melanoma have shown an average response rate of about 15-25% (Dillman et al., 1993; Tartour et al., 1992) . Therefore, since the overall response rate is low and treatment is associated with drug toxicity, many attempts have been made to predict clinical response. Up until now, only HLA phenotype has been correlated with response to IL-2 in melanoma (Marincola et al., 1992) . In renal cell carcinoma, patients with detectable serum interleukin 6 (IL-6) and/or CRP > 50 mg 1' before starting IL-2 treatment have a poor response to IL-2 (Blay et al., 1992) . Renal cell carcinoma and melanoma share some common features, such as IL-6 secretion and expression of membrane IL-6 receptor by tumour cells and the modulation of tumour cell proliferation by (Miki et al., 1989; Lee et al., 1992; Lu et al., 1992) . This prompted us to study serum IL-6 and CRP concentrations in melanoma patients prior to IL-2 therapy, in order to evaluate their predictive value for clinical outcome.
Materials and methods

Patients
A total of 30 patients with histologically proven metastatic melanoma, stage IV according to the American Join Commission on Cancer (AJCC) classification, were included in immunotherapy protocols with IL-2 aftf, obtaining their written informed consent. No other anti-cancer agents were given during the 3 weeks before IL-2 therapy. Patient characteristics are shown in Table I. According to the AJCC (Beahrs et al., 1988) and studies by Markowitz et al. (1991) and Balch et al. (1983) (Figure la) . Similarly, none of the 8 patients with elevated IL-6 levels responded to IL-2 ( Figure 912 E. TARTOUR et al. (Table II) . Finally, survival analysis revealed a clear correlation between a high serum IL-6 level and fatal outcome (Table II) . In fact, patients with high serum IL-6 levels had a median survival of 3 months compared with 9 months in patients with low serum IL-6 levels (P = 0.01 IL-6 (pg ml -1) Figure 1 Relationship between serum CRP and IL-6 levels before IL-2 therapy and clinical response. Responders (-) and non-responders (0) to IL-2 therapy were compared with regard to normal (<1O mg ml-') or pathological (>1O mg -') serum CRP (a), normal (<20 pg ml-') or elevated (> 20 pg ml-') serum IL-6 concentration (b), and to combined data, i.e. normal serum CRP and IL-6 levels vs elevated serum IL-6 and/or CRP levels (c). Statistical analyses were performed with the Fisher exact test. patients treated with these different protocols (data not shown). These results are in accordance with previous studies indicating a correlation between serum CRP and IL-6 levels and clinical response to IL-2 therapy in patients with renal cell carcinoma (Blay et al., 1992) and colorectal carcinoma (Broom et al., 1992) . Blay et al. found a good correlation between serum IL-6 and CRP levels which was less marked in this study.
We then wondered whether this poor IL-2 responder group corresponded to clinical prognostic groups. Patients with elevated serum IL-6 and/or CRP levels were not overrepresented in the poor prognosis group with statistical significance. No relationship between serum IL-6 or CRP levels and disease-free interval, site or number of metastases was demonstrated (data not shown).
Patients with elevated serum IL-6 levels had a shorter survival than patients with low serum IL-6 levels. This is similar to the results reported by Blay et al. (1992) , who found an association between elevated serum IL-6 levels and decreased survival in renal cell carcinoma.
The action of IL-6 on the immune system is complex, and both beneficial and adverse effects have been reported. enhances the cytotoxic activity of NK cells (Luger et al., 1989) , and an anti-tumour effect of recombinant IL-6 has been reported in mice (Mule et al., 1990) . When transplanted in mice, a lung adenocarcinoma transfected with a cDNA coding for IL-6 lost its tumorigenicity and induced an effective immune response (Porgador et al., 1992) . On the other hand, high IL-6 concentrations inhibit T-cell proliferative responses and tumour necrosis factor a (TNF-m) synthesis (Aderka et al., 1989; Zhou et al., 1991) . Lu et al. (1992) showed that the growth of melanoma cells obtained from early-stage (metastically incompetent) primary lesions is inhibited by IL-6. This growth-inhibitory effect was lost in the more advanced stage (metastatically competent) derived cell lines, which also exhibited an increase in resistance to other inhibitory factors such as IL-113, TNF-a and transforming growth factor P (TGF-P) (Lu et al., 1992) .
These resistance phenomena were often associated with spontaneous IL-6 secretion by these advanced-stage cell lines (Lu et al., 1993) . Therefore, this multicytokine resistance phenotype may explain the failure of IL-2 therapy in such patients, if IL-2 acts by inducing selective cytokines or inhibitory factors.
In conclusion, our study suggests that high serum IL-6 and/or CRP levels could constitute a prognostic factor to stratify IL-2-treated melanoma patients.
